Gretta Stone Gretta Stone is deputy vice president of policy & research at PhRMA, where she works to communicate the positive contribution of biopharmaceutical companies and their products. She manages a range of issues related to the R&D process, the value of medicines, FDA regulation, orphan drugs, and personalized medicine. In her more than twelve years at PhRMA she has authored many PhRMA reports and publications including the annual Biopharmaceutical Industry Profile, an overview of the sector and a go-to source of data on the industry. Gretta also serves on the board of the Society for Women’s Health Research, an organization dedicated to advancing our understanding of the biological differences in disease and advocating to enhance women’s health. Prior to joining PhRMA, Gretta worked in a lab researching language and the brain at Georgetown University, where she received a BS in biology.
Recent Posts
New report details the setbacks and challenges to Alzheimer’s research
By Gretta Stone | September 12, 2018
Illustrating the challenges of developing medicines to fight Alzheimer’s disease, a new analysis found that between 1998 and 2017, there were 146 unsuccessful medicines in clinical trials for...
Read More
ICYMI: Orphan drug development brings unique challenges
By Gretta Stone | May 21, 2018
A new report from the Tufts Center for the Study of Drug Development finds that it takes 2.3 years, or 18 percent, longer to develop an orphan drug compared with medicines to treat more common...
Read More
New report portrays flourishing pipeline
By Gretta Stone | July 18, 2017
It’s an exciting time to be working in the biopharmaceutical industry. Almost every day new headlines highlight remarkable new advances in the fight against disease. Some have called this the...
Read More
Using setbacks as stepping stones in Alzheimer’s research
By Gretta Stone | August 3, 2016
For decades, biopharmaceutical researchers have worked tirelessly in the pursuit of new treatments and cures for the costly and devastating Alzheimer’s disease. Advancing treatments for...
Read More
New Study Illustrates Biopharmaceutical Industry’s Commitment to Personalized Medicine
By Gretta Stone | May 20, 2015
Potential personalized medicines represent 42 percent of drugs in the pipeline. This new finding, from a survey by the Tufts Center for the Study for Drug Development (CSDD), is remarkably high,...
Read More
Medicare Monday (100)
340B Spotlight (39)
Cost & Consequence (0)
